You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)就舒格利單抗(PD-L1)及CS1003(PD-1)授予EQRx獨家授權
格隆匯 10-27 07:06

格隆匯 10 月 27日丨基石藥業-B(02616.HK)發佈公告,2020年10月26日,公司(“授權人”)與EQRx, INC.(“獲授權人”)訂立獨家授權合約,據此,授權人授予EQRx獨家授權,容許其在中國(包括台灣、香港特別行政區及澳門特別行政區)境外開發、及商業化基石藥業的抗PD-L1單克隆抗體舒格利單抗(CS1001)及抗PD-1單克隆抗體(CS1003)。

根據授權合約並按照其中的條款及條件,授權人有權收取1.5億美元的首付款,及最高可達11.5億美元的里程碑付款以及額外的分級特許權使用費。籤立授權合約後,在遵守授權合約規定的條款及條件前提下,除授權人及獲授權人於若干情況下共同另作協定外,獲授權人將負責承擔與大中華地區的外舒格利單抗及 CS1003的現有試驗及未來試驗的開發及監管事務相關的所有活動的費用。根據授權合約,EQRx須遵守慣常的排他性不競爭義務,而授權人與獲授權人須遵守慣常的相互陳述、保證、契約及彌償保證。

授權合約將充分發揮EQRx的創新業務模式及其獨特商業化能力等優勢,提升舒格利單抗和CS1003在與其他現有療法競爭中的優勢,並把這兩款藥物帶給全球腫瘤患者。此外,授權合約充分體現了這兩款藥物在全球市場的巨大商業潛力,併為基石藥業在關鍵戰略發展領域的投資提供了即時資金支援。故此,董事會相信授權合約及其項下擬進行的交易符合公司及其股東的整體最佳利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account